// App-Quantinova.ai

OP0193 (2022) : EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS

Researchers

Presenter

  • F. De Benedetti

Principal Investigators

  • A. Grom

  • P. Brogan

  • C. Bracaglia

  • M. Pardeo

  • G. Marucci

  • D. Eleftheriou

  • C. Papadopoulou

  • P. Quartier

  • J. Anton

  • R. Frederiksen

  • V. Asnaghi

  • C. de Min

Medical Centers

  • Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, United States of America

  • Great Ormond Street Hospital NHS Foundation Trust, UCL Institute of Child Health, London, United Kingdom

  • Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, IMAGINE Institute, RAISE Reference Center, Pediatric Immuno-Hematology and Rheumatology Unit, Paris, France

  • University of Barcelona, Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, Barcelona, Spain

  • Swedish Orphan Biovitrum AG (Sobi), Clinical Science, Basel, Switzerland

Locations

  • Italy

  • United States

  • United Kingdom

  • France

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Macrophage activation syndrome

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • Interferon-gamma

  • Albumin/creatinine

Drug/Treatment

  • Interferon Gamma

  • Glucocorticoid

  • NI0501

  • Interferon

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT03311854

  • NCT02069899

Sponsors

  • Swedish Orphan Biovitrum

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved